Annual report
4544.TEDINET S100TMPA
Period2023-04-01 → 2024-03-31
Filed2024-06-19
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 154
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥236.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥260.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥272.9bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥223.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥188.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | −¥4.0bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥23.4bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | −¥7.2bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥22.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥47.4bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥25.5bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.5bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥7.6bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥22.9bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥7.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥15.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.6bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥17.5bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥516m | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥7.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥15.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥290.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥297.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥286.6bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥252.8bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥219.4bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥148.3bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥147.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥142.5bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥150.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥140.2bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥115.3bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥103.2bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥39.9bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥44.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥39.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥44.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥43.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥36.2bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥16.6bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥32.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥55.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥35.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥15.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥16.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥29.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥30.9bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥28.3bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥21.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥5.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥21.7bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥8.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-132.77 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥275.52 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥519.55 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥306.38 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-9.06 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥275.5 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥519.42 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥306.32 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥2,506.5 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,635.26 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,463.33 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,020.01 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,809.18 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 49.0% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.3% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.9% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.6% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.0% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 10.8% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 23.2% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 16.0% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 5,295 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 5,437 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 5,444 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 5,897 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 5,968 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥23.4bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥24.7bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥17.1bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥15.0bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥40.1bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥11.7bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥13.7bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥8.4bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥12.4bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.2bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.7bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥32.7bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥8.2bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥11.3bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥9.7bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥12.9bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥5.9bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥115m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥27.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥178.2bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥182.4bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥173.7bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥167.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥161.3bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥111.5bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥119.3bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥66.7bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥63.1bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥58.8bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥60.5bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥66.9bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥35.7bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥37.4bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥170.4 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥225.98 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥103.08 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥2.02 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥485.53 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥170.39 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥225.97 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥103.05 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥2.02 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥485.42 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥125 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥125 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥125 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥144 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥130 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,172.79 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,108.11 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,032.83 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,058.77 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,171.23 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 37.4% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.6% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.8% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.0% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 14.9% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 21.1% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.9% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.2% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 48.7% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 57,473,822 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 57,471,867 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 57,446,657 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 57,416,407 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 57,387,861 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 400 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 392 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 330 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 304 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 322 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 72
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥949m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥1.5bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥5.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥5.9bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥35.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥5.8bn |
| Clinical Lab Testing Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥9.9bn |
| Clinical Lab Testing Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥12.3bn |
| Clinical Lab Testing Businessreportable segment | employees | at 2024-03-31 | 2023 pure |
| Clinical Lab Testing Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥147.0bn |
| Clinical Lab Testing Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥146.7bn |
| Clinical Lab Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥258m |
| Clinical Lab Testing Businessreportable segment | segment assets | at 2024-03-31 | ¥117.9bn |
| Clinical Lab Testing Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥12.5bn |
| In Vitro Diagnostics Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥6.9bn |
| In Vitro Diagnostics Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| In Vitro Diagnostics Businessreportable segment | employees | at 2024-03-31 | 1103 pure |
| In Vitro Diagnostics Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥67.5bn |
| In Vitro Diagnostics Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥61.9bn |
| In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥5.6bn |
| In Vitro Diagnostics Businessreportable segment | segment assets | at 2024-03-31 | ¥124.6bn |
| In Vitro Diagnostics Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥12.9bn |
| Sterilization And Related Servicesreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥1.3bn |
| Sterilization And Related Servicesreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥1.7bn |
| Sterilization And Related Servicesreportable segment | employees | at 2024-03-31 | 1006 pure |
| Sterilization And Related Servicesreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥28.3bn |
| Sterilization And Related Servicesreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥28.3bn |
| Sterilization And Related Servicesreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥5m |
| Sterilization And Related Servicesreportable segment | segment assets | at 2024-03-31 | ¥13.1bn |
| Sterilization And Related Servicesreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.3bn |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥18.2bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥18.9bn |
| —segment total | employees | at 2024-03-31 | 4132 pure |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥242.8bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥236.9bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥5.9bn |
| —segment total | segment assets | at 2024-03-31 | ¥255.7bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.7bn |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥1.7bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥7.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥7.9bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥23.8bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥4.5bn |
| Clinical Lab Testing Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥10.9bn |
| Clinical Lab Testing Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥12.0bn |
| Clinical Lab Testing Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥163.4bn |
| Clinical Lab Testing Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥163.1bn |
| Clinical Lab Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥293m |
| Clinical Lab Testing Businessreportable segment | segment assets | at 2023-03-31 | ¥131.1bn |
| Clinical Lab Testing Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥279m |
| In Vitro Diagnostics Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥8.4bn |
| In Vitro Diagnostics Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥4.2bn |
| In Vitro Diagnostics Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥77.7bn |
| In Vitro Diagnostics Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥70.1bn |
| In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥7.6bn |
| In Vitro Diagnostics Businessreportable segment | segment assets | at 2023-03-31 | ¥129.2bn |
| In Vitro Diagnostics Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥26.5bn |
| Sterilization And Related Servicesreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥2.1bn |
| Sterilization And Related Servicesreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥1.7bn |
| Sterilization And Related Servicesreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥27.8bn |
| Sterilization And Related Servicesreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥27.8bn |
| Sterilization And Related Servicesreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥17m |
| Sterilization And Related Servicesreportable segment | segment assets | at 2023-03-31 | ¥13.8bn |
| Sterilization And Related Servicesreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥21.4bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥17.8bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥268.8bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥260.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥7.9bn |
| —segment total | segment assets | at 2023-03-31 | ¥274.1bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥27.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,846
| Item | Context | Value | Unit |
|---|---|---|---|
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.0128 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.4057 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0001 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.1603 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 11278200 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.1971 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 3960500 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.0692 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 2486700 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0435 | |
| Number of shares held | CurrentYearInstant_No4MajorShareholdersMember | 2205300 | |
| Shareholding ratio | CurrentYearInstant_No4MajorShareholdersMember | 0.0385 | |
| Number of shares held | CurrentYearInstant_No5MajorShareholdersMember | 1705400 | |
| Shareholding ratio | CurrentYearInstant_No5MajorShareholdersMember | 0.0298 | |
| Number of shares held | CurrentYearInstant_No6MajorShareholdersMember | 1538600 | |
| Shareholding ratio | CurrentYearInstant_No6MajorShareholdersMember | 0.0269 | |
| Number of shares held | CurrentYearInstant_No7MajorShareholdersMember | 1272200 | |
| Shareholding ratio | CurrentYearInstant_No7MajorShareholdersMember | 0.0222 | |
| Number of shares held | CurrentYearInstant_No8MajorShareholdersMember | 1129200 | |
| Shareholding ratio | CurrentYearInstant_No8MajorShareholdersMember | 0.0197 | |
| Number of shares held | CurrentYearInstant_No9MajorShareholdersMember | 1054400 | |
| Shareholding ratio | CurrentYearInstant_No9MajorShareholdersMember | 0.0184 | |
| Number of shares held | CurrentYearInstant_No10MajorShareholdersMember | 1040600 | |
| Shareholding ratio | CurrentYearInstant_No10MajorShareholdersMember | 0.0182 | |
| Number of shares held | CurrentYearInstant | 27671200 | |
| Shareholding ratio | CurrentYearInstant | 0.4837 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 262100 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 57090100 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 570901 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 121622 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 57473822 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 570901 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 262100 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 262100 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0046 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | 262100 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | 262100 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | 0.0046 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row1Member | 3547000000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row1Member | 62 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row2Member | 3604000000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row2Member | 63 | |
| Number of male directors and other officers | FilingDateInstant | 12 | |
| Number of female directors and other officers | FilingDateInstant | 2 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |